AGEN — AGENUS INC
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1098972 ·
Last close
$6.21
Market Cap
$280.98M
52W High
$10.31
52W Low
$2.71
ADV30
757,488
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 31,488,000 | 19,842,000 | 11,408,000 | 2,734,000 | 245,546,000 | 66,936,000 | 357,698,000 |
| Jun 2026 | 34,518,000 | 19,759,000 | 11,293,000 | -550,000 | 172,692,000 | 18,738,000 | 378,542,000 |
| Mar 2026 | 33,736,000 | 21,914,000 | 15,054,000 | 39,226,000 | 186,456,000 | 34,996,000 | 414,439,000 |
| Dec 2025 | 34,204,000 | 26,693,000 | 14,398,000 | -10,578,000 | 226,798,000 | 2,998,000 | 504,659,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-98,504,000
Investing CF
$70,075,000
Financing CF
$35,748,000
CapEx
$-6,000
Dividends Paid
—
Buybacks
$-54,000
EPS Diluted TTM
$1.95
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-2,144,089,000
Inventory
—
Receivables
$22,341,000
ST Investments
—
EBIT TTM
$151,038,000
Pretax Income TTM
$91,938,000
Interest Exp TTM
$59,100,000
Analysts
3
Yahoo Snapshot (yfinance, live)
Total Revenue
$133,946,000
EBITDA
$54,362,000
Free Cash Flow
$-8,132,000
Enterprise Value
$269,256,544
Total Cash
$86,936,000
Total Debt
$39,464,000
Shares Out
45,246,510
Trailing EPS
$0.23
Book Value
$-2.33
ROE
—
ROA
13.6%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 114,196,000 | -20,556,000 | 115,000 | 226,798,000 | 504,659,000 | -271,111,000 | -77,195,000 |
| Dec 2024 | 103,463,000 | -124,429,000 | -227,212,000 | 226,271,000 | 532,695,000 | -326,380,000 | -158,315,000 |
| Dec 2023 | 156,314,000 | -160,105,000 | -245,761,000 | 313,913,000 | 462,295,000 | -160,331,000 | -224,202,000 |
| Dec 2022 | 98,024,000 | -180,242,000 | -220,074,000 | 413,556,000 | 468,458,000 | -61,278,000 | -175,373,000 |
TTM Snapshot
Revenues TTM
$132,693,000
NetIncome TTM
$91,796,000
OpCashFlow TTM
—
Assets (Latest)
$172,692,000
Forward EPS
$-0.16
Max Pain — expiry 2027-01-15
max pain strike: $5.00 · spot: $6.40 · call oi: 4,845 · put oi: 1,223
Expected Move to 2027-01-15:
±$1.85
(28.91%) —
implied range
$4.55 –
$8.25
· ATM straddle on $6.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| EDIT | Editas Medicine, Inc. | $281.67M | $1.83 | — |
| EIKN | Eikon Therapeutics, Inc. | $279.06M | $5.15 | — |
| TRXB | TRex Bio, Inc. | $274.46M | $10.00 | — |
| AUTL | Autolus Therapeutics plc | $290.12M | $1.09 | — |
| AGMB | AgomAb Therapeutics NV | $291.55M | $5.92 | — |
News headlines (Yahoo Finance, 1h cache)
Agenus' Q3 Earnings Match Estimates, Revenues Miss Mark, Stock Down
2026-11-06 15:47 · Yahoo
Agenus Reports More Than Half of Patients with Refractory MSS Metastatic Colorectal Cancer Achieved Long-Term Survival Following BOT+BAL Treatment at SITC 2026
2026-11-06 14:00 · Yahoo
Agenus (AGEN) Q3 Earnings Meet Estimates
2026-11-06 00:00 · Yahoo
Agenus: Q3 Earnings Snapshot
2026-11-05 23:39 · Yahoo
Agenus Targets Phase 3 Colon Cancer Trial as Financing Hinges on Enrollment Milestones
2026-11-05 21:14 · Yahoo
Agenus Reports Third Quarter 2026 Results, Highlighted by First Marketing Authorizations for BOT+BAL and Global Investigator Support for Phase 3 ROBBIN Study
2026-11-05 12:30 · Yahoo
Agenus to Participate in Rodman & Renshaw Virtual Fireside Chat
2026-11-02 23:05 · Yahoo
Agenus Announces Nature Medicine Publication of Multicenter UNICORN Phase 2 Trial Demonstrating Deep Responses with Neoadjuvant BOT+BAL in Resectable Colon Cancer
2026-11-02 11:42 · Yahoo
Agenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study at ESMO 2026
2026-10-25 11:00 · Yahoo
Agenus to Provide Third Quarter 2026 Financial Report and Development Update
2026-10-22 20:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.